Cardio Diagnostics CEO Outlines India Expansion and Medicare Progress on BioMedWire Podcast
Cardio Diagnostics Holdings CEO Dr. Meesha Dogan discussed the company's precision cardiovascular medicine strategy, including expansion into India via partnerships and completion of key Medicare reimbursement steps.
Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing its mission to revolutionize cardiovascular disease prevention and early detection through precision medicine, as outlined by CEO and Co-Founder Dr. Meesha Dogan in a recent appearance on The BioMedWire Podcast. The company, which leverages epigenetics, genetics, and artificial intelligence to develop personalized clinical tests, is making notable progress in both domestic and international markets.
During the podcast, Dogan highlighted Cardio Diagnostics' expansion into India through strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs, two established healthcare entities. This move positions the company to address the growing burden of cardiovascular disease in one of the world's most populous nations, where early detection and prevention are critical. The partnerships are expected to facilitate the distribution and adoption of Cardio Diagnostics' AI-driven tests in the Indian healthcare system.
On the regulatory front, Dogan provided an update on the company's progress through the Medicare reimbursement process. She noted that the CPT coding and payment steps have been completed, a significant milestone that paves the way for broader coverage. However, the coverage determination phase remains underway, which will ultimately dictate the extent to which Medicare beneficiaries can access Cardio Diagnostics' tests. The completion of these steps underscores the company's commitment to navigating the complex U.S. healthcare reimbursement landscape.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. Its proprietary Integrated Genetic-Epigenetic Engine, or Core Technology, forms the backbone of its clinical tests, which are designed to improve outcomes for patients at risk of heart disease.
The company's appearance on The BioMedWire Podcast comes at a time when cardiovascular disease remains the leading cause of death globally, highlighting the importance of innovative approaches to early detection and personalized treatment. By combining AI with genetic and epigenetic insights, Cardio Diagnostics is positioned to offer solutions that go beyond traditional risk factors.
For more information on Cardio Diagnostics and its latest developments, visit the company's newsroom at https://ibn.fm/CDIO. The full press release is also available at https://ibn.fm/8DJcl.